Access
To read this story in full you will need to login or make a payment (see right).
Insight
Nature 441, 451-456 (25 May 2006) | doi:10.1038/nature04873; Published online 24 May 2006
Open Innovation Challenges
-
Efficient Chromosome Doubling: Plant Cell Division
The Seeker is looking for an efficient chromosome doubling method in plants and in particular, metho...
-
Fast Growth of Transformed Soybean Shoots
A method for accelerating growth of soybean shoots is desired.
- More Challenges
- Powered by:
nature jobs
Canada Excellence Research Chair in Biofuels and Biorefining Innovation
- University of British Columbia
- Vancouver, British Columbia Canada
Research Fellows in Pluripotent Stem Cell Technology
- The University of Nottingham
- Nottingham, UK
Review Article Validating cancer drug targets
John D. Benson1, Ying-Nan P. Chen1, Susan A. Cornell-Kennon1, Marion Dorsch1, Sunkyu Kim1, Magdalena Leszczyniecka1, William R. Sellers1 & Christoph Lengauer1
Abstract
A cancer drug target is only truly validated by demonstrating that a given therapeutic agent is clinically effective and acts through the target against which it was designed. Nevertheless, it is desirable to declare an early-stage drug target as 'validated' before investing in a full-scale drug discovery programme dedicated to it. Although the outcome of validation studies can guide cancer research programmes, strictly defined universal validation criteria have not been established.
To read this story in full you will need to login or make a payment (see right).
